Phase III study of Covaxin reports efficacy of 80.6% in COVID-19 – Ocugen/Bharat Biotech
Ocugen announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase III study of Covaxin, a whole virion inactivated COVID-19… read more.